AURA
HEALTHCAREAura Biosciences Inc
What's Moving AURA Today?
No stock-specific AI insight has been generated for AURA yet. Check back soon — insights are generated from recent news analysis.
Market Briefings featuring AURA
52-Week Range
$7.10
Fundamentals
Trading
AURA News
20 articles- Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal MelanomaYahoo Finance·Jun 1, 2026
- Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial AdvancesMarketbeat·May 27, 2026
- Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder DataMarketbeat·May 20, 2026
- Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 19, 2026
- Aura Biosciences to Participate in Upcoming Investor ConferencesYahoo Finance·May 12, 2026
- Aura Biosciences Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 11, 2026
- Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesYahoo Finance·May 5, 2026
- Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded WarrantsYahoo Finance·May 4, 2026
- Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·May 4, 2026
- Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment CompletionYahoo Finance·May 4, 2026
- Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?Yahoo Finance·Apr 22, 2026
- Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?Yahoo Finance·Apr 20, 2026
- Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?Yahoo Finance·Apr 10, 2026
- Auranova Announces Closing of Private Placement of Flow-Through SharesYahoo Finance·Apr 7, 2026
- Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Apr 6, 2026
- Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should KnowYahoo Finance·Apr 2, 2026
- Auranova Resources and Kenorland Minerals Commence Spring Drill Program at South Uchi ProjectYahoo Finance·Apr 1, 2026
- Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsYahoo Finance·Mar 30, 2026
- Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?Yahoo Finance·Mar 20, 2026
- Auranova Resources and Kenorland Minerals Announce Upcoming 2026 Spring Drill Program at The South Uchi Project, OntarioYahoo Finance·Mar 18, 2026
All 20 articles loaded
Price Data
52-Week Range
$7.10
Fundamentals
Trading
About Aura Biosciences Inc
Aura Biosciences Inc is an innovative clinical-stage biotechnology firm dedicated to revolutionizing cancer treatment through its proprietary virus-like particle (VLP) technology. The company's flagship investigational drug, AU-011, specifically targets ocular cancer cells, aiming to eradicate malignancies while preserving healthy tissue—a testament to its advancements in precision oncology. With a comprehensive clinical pipeline addressing significant unmet needs in cancer care and a seasoned management team at the helm, Aura is well-positioned for impactful contributions to the oncology landscape. Additionally, its strategic collaborations enhance its capacity for innovation, aligning with the evolving demand for targeted therapies within the healthcare sector.